Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer

Highlights • Afatinib, erlotinib, and gefitinib are available for EGFR mutation-positive NSCLC. • Severe rash and diarrhea were more frequent with afatinib treatment. • Severe hepatotoxicity was more frequent with gefitinib treatment.

Saved in:
Bibliographic Details
Published in:Lung cancer (Amsterdam, Netherlands) Netherlands), 2015-04, Vol.88 (1), p.74-79
Main Authors: Takeda, Masayuki, Okamoto, Isamu, Nakagawa, Kazuhiko
Format: Article
Language:English
Subjects:
Afatinib
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Carcinoma, Non-Small-Cell Lung - mortality
Chemical and Drug Induced Liver Injury - etiology
ErbB Receptors - genetics
Erlotinib Hydrochloride - adverse effects
Erlotinib Hydrochloride - therapeutic use
Gefitinib
Hematology, Oncology and Palliative Medicine
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Lung Neoplasms - mortality
Mutation
Pulmonary/Respiratory
Quinazolines - adverse effects
Quinazolines - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Afatinib, erlotinib, and gefitinib are available for EGFR mutation-positive NSCLC. • Severe rash and diarrhea were more frequent with afatinib treatment. • Severe hepatotoxicity was more frequent with gefitinib treatment.
ISSN:0169-5002
1872-8332
1872-8332
DOI:10.1016/j.lungcan.2015.01.026